XML 52 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6
Business Segment Information (Tables)
9 Months Ended
Jan. 31, 2013
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]

The following tables summarize, for the periods indicated, operating results by business segment (in thousands):

 

          Translational              
    Personalized     Oncology     Unallocated        
    Oncology     Solutions     Corporate        
Three Months Ended January 31, 2013   Solutions (POS)     (TOS)     Overhead     Consolidated  
Net revenue   $ 473     $ 2,444     $ -     $ 2,917  
Direct cost of services     (661 )     (561 )     -       (1,222 )
Sales and marketing costs     (361 )     (220 )     -       (581 )
Other operating expenses     -       (627 )     (637 )     (1,264 )
Stock- based compensation expense (1)     -       -       (570 )     (570 )
                                 
Segment profit (loss)   $ (549 )   $ 1,036     $ (1,207 )   $ (720 )

 

          Translational              
    Personalized     Oncology     Unallocated        
    Oncology     Solutions     Corporate        
Three Months Ended January 31, 2012   Solutions (POS)     (TOS)     Overhead     Consolidated  
Net revenue   $ 649     $ 1,747     $ -     $ 2,396  
Direct cost of services     (528 )     (801 )     -       (1,329 )
Sales and marketing costs     (242 )     (175 )     -       (417 )
Other operating expenses     -       (851 )     (829 )     (1,680 )
Stock- based compensation expense (1)     -       -       (743 )     (743 )
                                 
Segment profit (loss)   $ (121 )   $ (80 )   $ (1,572 )   $ (1,773 )

 

          Translational              
    Personalized     Oncology     Unallocated        
    Oncology     Solutions     Corporate        
Nine Months Ended January 31, 2013   Solutions (POS)     (TOS)     Overhead     Consolidated  
Net revenue   $ 1,850     $ 4,631     $ -     $ 6,481  
Direct cost of services     (2,030 )     (1,740 )     -       (3,770 )
Sales and marketing costs     (495 )     (636 )     -       (1,131 )
Other operating expenses     -       (1,463 )     (2,418 )     (3,881 )
Stock- based compensation expense (1)     -       -       (1,934 )     (1,934 )
                                 
Segment profit (loss)   $ (675 )   $ 792     $ (4,352 )   $ (4,235 )

 

          Translational              
    Personalized     Oncology     Unallocated        
    Oncology     Solutions     Corporate        
Nine Months Ended January 31, 2012   Solutions (POS)     (TOS)     Overhead     Consolidated  
Net revenue   $ 1,837     $ 3,931     $ -     $ 5,768  
Direct cost of services     (1,463 )     (1,904 )     -       (3,367 )
Sales and marketing costs     (718 )     (626 )     -       (1,344 )
Other operating expenses     -       (2,419 )     (2,489 )     (4,908 )
Stock- based compensation expense (1)     -       -       (2,612 )     (2,612 )
                                 
Segment profit (loss)   $ (344 )   $ (1,018 )   $ (5,101 )   $ (6,463 )

 

(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.